Pathways Task Force Subcommittee: Standard Operating Procedures

Mission Statement: The mission of Value Pathways powered by NCCN™ is to facilitate the delivery of high quality, high value cancer care to our patients through a physician-driven network-supported program utilizing evidence-based medicine.

Pathway Development/Maintenance Process

1. PURPOSE:
   a. The purpose of this document is to outline the stakeholders, processes and expectations for developing and maintaining clinical, evidence-based medicine pathways (Value Pathways powered by NCCN™) that are governed by The US Oncology Network’s Pathways Task Force (PTF).

2. DEFINITIONS
   a. Pathways Task Force (PTF)
      i. The PTF is a sub-committee of the US Oncology Network P&T committee which governs the development and maintenance of The US Oncology Network’s Pathways Program: Value Pathways powered by NCCN™.
      ii. The PTF advises and makes recommendations to the P&T Committee and The US Oncology Network for incorporation of evidence-based, cost-effective treatment via Value Pathways which supports:
           1. The use of clinical trials;
           2. Evidence-based data for specific cancer types based on disease and patient-specific characteristics
           3. Cost effective systemic treatment;
           4. Continuous monitoring and analysis of results and outcomes.
   b. Value Pathways powered by NCCN™
      i. Joint evidence and value-based treatment guidelines developed and maintained by The US Oncology PTF in collaboration with designated NCCN Clinical Practice Guidelines in Oncology® disease committee members.
      ii. Value Pathways powered by NCCN are a subset of the NCCN Clinical Practice Guidelines in Oncology.
   c. Technology Platform: Clear Value Plus™ (CVP): the decision support tool that delivers Value Pathways powered by NCCN and NCCN Clinical Practice Guidelines in Oncology content to practices by interfacing with contracted EHRs.

3. PTF COMPOSITION AND APPOINTMENT (APPENDIX A)
   a. Each pathway will have a corresponding Disease Chair who will oversee development and maintenance of said Pathway. Each Disease Chair is a full voting member of the PTF.
b. Voting members of the PTF within The US Oncology Network are appointed by the P&T Committee Chairman, McKesson Specialty Health Chief Medical Officer and the PTF Chairman.

c. Terms of membership will be reviewed by the PTF Chair and Executive Lead annually

d. NCCN will appoint up to 3 physician members for each Pathway as voting members to be involved in the review and incorporation of data into Value Pathways development and update. The physicians will be existing members of the NCCN Guideline Panel for the disease.

4. PTF MEETINGS
   a. PTF meetings will take place monthly on the first Thursday of each month, or as determined by the PTF Executive Lead.
   b. Semi-annual P&T meetings may include in-person meetings.

5. DEVELOPMENT/REVIEW PROCESS
   a. Pathway Updates – General Guidelines
      i. A process for reviewing and updating Pathways will be followed and timed to correspond with implementation of content into technology platforms (EHRs and Clear Value Plus)
      ii. Evidence to be considered for Pathways will be reviewed during monthly PTF calls.
      iii. Each Pathway will be reviewed for updates/changes at least once per year depending on the available evidence. Reviews will include, but are not limited to:
         1. Evidence Tables for any regimens to be considered for addition to Pathways
         2. Estimate of financial impact to payer and patient
            a. Medicare reimbursement will correspond to the most recently published Medicare reimbursement rates (quarter/year)
   b. External Pharmacoeconomic Submissions
      i. External submissions based on pharmacoeconomic data may be accepted for PTF review.
         1. All complete submissions will be reviewed and published online in accordance with guidelines from the MSH website (https://oncology.mckessonspecialtyhealth.com/clinical-tools/value-pathways)
      ii. A summary of PTF discussion and aggregated votes will be included for display on the MSH site along with the original submission documents once P&T voting is complete
         1. The final PTF decision is communicated to the submitter within 120 days of a confirmed complete submission
Appendix A: Physician Composition and Appointment 2018

PTF Chairman:
- Lalan Wilfong, MD – PTF Chairman, TX

Voting Members (11 + PTF Chairman)
- David Andorsky, MD- Hematology Chair (MM, leukemia): CO
- John Burke, MD- Hematology Chair (Lymphoma): CO
- Lance Cowey, MD- Melanoma Chair: TX
- Neelima Denduluri, MD- Breast Co-Chair: VA
- Russ Hoverman, MD, PhD-ACP Chair: TX
- Lynne Knowles, MD- Gyn Onc Chair: TX
- Kartik Konduri, MD- Lung Cancer, H&N Cancer Chair: TX
- Tim Larson, MD- GI Cancer Chair (Colon/Rectal, Anal): MN
- Debra Patt, MD, MPH- Breast Cancer Chair: TX
- Scott Paulson, MD- Neuroendocrine Cancer Chair, GI Cancer Chair (Pancreas, Gastric/Esophageal): TX
- Ian Schnadig, MD- GU Cancer Chair: OR

Members-at-large (non-voting):
- Barry Brooks, MD (P&T Chair)
- Les Busby, MD (P&T Vice-Chair)
- Mark Sitarik, MD
- Nick Robert, MD
- Marcus Neubauer, MD (Chief Medical Officer)

NCCN Disease Panel Members: 3/disease

Bladder Cancer
- Terence Friedlander, MD: University of California, San Francisco
- Thomas Flaig, MD: University of Colorado, Denver
- Elizabeth Plimack, MD: Fox Chase Cancer Center

Breast Cancer
- Ben Anderson, MD: University of Washington (SCCA)
- William J. Gradishar, MD: Northwestern University
- John Ward, MD: University of Utah

Cervical Cancer
- Susana Campos, MD: Dana-Farber Cancer Institute
- Wui-Jin Koh, MD: University of Washington (SCCA)
- Nadeem Abu Rustum, MD: Memorial Sloan-Kettering Cancer Center

Chronic Lymphocytic Leukemia
- John C. Byrd, MD: The Ohio State University
- Asher Chanan-Khan, MD: Mayo Clinic Cancer Center
- William Weirda, MD: MD Anderson Cancer Center
Chronic Myeloid Leukemia
- Jessica Altman, MD: Northwestern University
- Jerald P. Radich, MD: Fred Hutchinson Cancer Research Center
- Neil Shah, MD: University of California, San Francisco

Colon/Rectal/Anal Cancers
- Al B. Benson, MD: Northwestern University
- Alan P. Venook, MD: University of California, San Francisco
- Christopher G. Willett, MD: Duke University

Gastric/Esophageal Cancers
- Jaffer Ajani, MD: MD Anderson Cancer Center
- David Ilson, MD: Memorial Sloan-Kettering Cancer Center
- Mary Mulcahy, MD: Northwestern University

Head and Neck Cancer
- Jill Gilbert, MD: Vanderbilt University
- David G. Pfister, MD: Memorial Sloan-Kettering Cancer Center
- Sharon Spencer, MD: University of Alabama-Birmingham Medical Center

Hodgkin Lymphoma
- Richard Hoppe, MD: Stanford University
- Mark Kaminski, MD: University of Michigan
- Joseph Moore, MD: Duke University

Kidney Cancer
- Toni Choueiri, MD: Dana-Farber Cancer Institute
- Eric Jonasch, MD: MD Anderson Cancer Center
- Robert Motzer, MD: Memorial Sloan-Kettering Cancer Center

Melanoma
- Richard Joseph, MD: Mayo Clinic Cancer Center
- Anthony Olszanski, MD: Fox Chase Cancer Center
- John Thompson, MD: University of Washington (SCCA)

Multiple Myeloma
- Natalie Callander, MD: University of Wisconsin Carbone Cancer Center
- Carol Ann Huff, MD: Johns Hopkins Medical Institute
- Shaji Kumar, MD: Mayo Clinic Cancer Center

Myelodysplastic Syndrome
- Peter Greenberg, MD: Stanford University
- Margaret O'Donnell, MD: City of Hope
- Paul Shami, MD: University of Utah

Neuroendocrine Tumors
- Emily Bergsland, MD: University of California, San Francisco
• Matthew Kulke, MD: Dana-Farber Cancer Institute
• Manisha Shah, MD: The Ohio State University

Non-Hodgkin’s Lymphoma
• Leo Gordon, MD: Northwestern University
• Thomas Habermann, MD: Mayo Clinic Cancer Center
• Andrew Zelenetz, MD: Memorial Slone-Kettering Cancer Center

Non-Small Cell Lung Cancer
• David S. Ettinger, MD: Johns Hopkins Medical Institute
• Renato Martins, MD, MPH: University of Washington (SCCA)
• Doug E. Wood, MD: University of Washington (SCCA)

Ovarian Cancer
• Deborah K. Armstrong, MD: Johns Hopkins Medical Institute
• Carolyn Johnston, MD: University of Michigan
• Steven C. Plaxe, MD: UC San Diego Moores Cancer Center

Pancreatic Cancer
• Eileen O’Reilly: Memorial Slone-Kettering Cancer Center
• Margaret Tempero, MD: University of California, San Francisco
• Mokenge Malafa, MD: Moffitt Cancer Center

Prostate Cancer
• Celestia Higano, MD: University of Washington (SCCA)
• James L. Mohler, MD: Roswell Park Cancer Institute
• Sandy Srinivas, MD: Stanford University

Small Cell Lung Cancer
• Gregory Kalemkerian, MD: University of Michigan
• Billy W. Loo, Jr., MD, PhD: Stanford University
• Wallace Akerley, MD: University of Utah